Acute coronary syndromes: Finding meaning in OASIS 7

The Lancet

Volumn 376, Issue 9748, 2010, Pages 1203-1205

  Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; BYPASS SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE;

EID: 77957977532     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61262-7     Document Type: Note

References (13)

1. SR Mehta, CP Cannon, KA Fox Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials JAMA 293 2005 2908 2917
2. EC Keeley, JA Boura, CL Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20
3. VL Serebruany, SR Steinhubl, PB Berger, AI Malinin, DL Bhatt, EJ Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
4. D Sibbing, S Braun, T Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
5. T Cuisset, G Cayla, C Frere Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non ST-elevation acute coronary syndrome: shifting from antiplatelet resistance to bleeding risk assessment EuroIntervention 5 2009 325 329
6. SJ Pocock, R Mehran, TC Clayton Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the acute catheterization and urgent intervention triage strategy trial Circulation 121 2010 43 51
7. SR Mehta, J-F Tanguay, JW Eikelboom on behalf of the CURRENT-OASIS 7 trial investigators Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 2010 10.1016/S0140-6736(10)61088-4 published online Sept 1.
8. M O'Riordan CURRENT OASIS-7: benefit to doubling clopidogrel dose in ACS patients undergoing PCI http://www.theheart.org/article/995967.do Aug 30, 2009 (accessed Aug 23, 2010).
9. GW Stone Ticagrelor in ACS: redefining a new standard of care? Lancet 375 2010 263 265
10. DM Roden, AR Shuldiner Responding to the clopidogrel warning by the US Food and Drug Administration: real life is complicated Circulation 122 2010 445 448
11. G Dangas, R Mehran, G Guagliumi for the HORIZONS-AMI trial investigators Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial J Am Coll Cardiol 54 2009 1438 1446
12. M Lotrionte, GG Biondi-Zoccai, P Agostoni Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Am J Cardiol 100 2007 1199 1206
13. AstraZeneca Ticagrelor: NDA 22 433. Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM220197.pdf June 23, 2010 (accessed Aug 7, 2010).